GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS

Great Novel Therapeutics Biotech & Medicals

7427

TW0007427007

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
52 ^TWD	0.00%		-1.52%	-22.16%

03-20	Great Novel Therapeutics Biotech & Medicals Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Great Novel Therapeutics Biotech & Medicals(TPEX:7427) added to S&P Global BMI Index	CI

Great Novel Therapeutics Biotech & Medicals(TPEX:7427) added to S&P Global BMI Index

September 18, 2023 at 12:00 am

Latest news about Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Great Novel Therapeutics Biotech & Medicals(TPEX:7427) added to S&P Global BMI Index	23-09-18	CI
Great Novel Therapeutics Biotech & Medicals Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-13	CI
Great Novel Therapeutics Biotech & Medicals Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Great Novel Therapeutics Biotech & Medicals Reports Earnings Results for the Nine Months Ended September 30, 2022	23-03-14	CI
Great Novel Therapeutics Biotech & Medicals Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-12	CI
GNT Biotech & Medicals Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Gnt Biotech & Medicals Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-12	CI
GNT Biotech & Medicals Corporation has completed an IPO in the amount of TWD 40 million.	21-07-08	CI
GNT Biotech & Medicals Corporation has filed an IPO in the amount of TWD 40 million.	20-11-27	CI

Chart Great Novel Therapeutics Biotech & Medicals

Duration

Period

Chart Great Novel Therapeutics Biotech & Medicals

More charts

GNT Biotech & Medicals Corp is a Taiwan-based company mainly engaged in the research, development and clinical trials of oral anti-cancer targeted new drugs. The main product is the oral anti-cancer targeted new drug TM/Kepida, which is mainly used for the treatment of relapsed and refractory peripheral T-cell lymphoma (R/R PTCL) and ER+/Her-2-advanced breast cancer (ER+/Her-2-BC). The Company is also engaged in the research and development of tumor immunotherapies. The products include GNTbm-CC-01 and GNTbm-CC-02, which are tumor microenvironment regulator new drug combinations, as well as GNTbm-38, which is surface immunomodulator.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GREAT NOVEL THERAPEUTICS BIOTECH & MEDICALS	-22.16%	62.15M
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B

Other Biotechnology & Medical Research